Heat shock protein 70/peptide complexes: Potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Tischer, Sabine ^a   Basila, Megan ^a   Maecker Kolhoff, Britta ^a   Immenschuh, Stephan ^a   Oelke, Mathias ^b   Blasczyk, Rainer ^a   Eiz Vesper, Britta ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; GRANZYME B; HEAT SHOCK PROTEIN 70; HEME OXYGENASE 1; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; ANTIVIRUS AGENT; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; GRANZYME; MATRIX PROTEIN; MESSENGER RNA; PEPTIDE; PHOSPHOPROTEIN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL EXPANSION; CELL FUNCTION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; PROTEIN DEGRADATION; PROTEIN SECRETION; PROTEIN TRANSPORT; UPREGULATION; CYTOLOGY; CYTOTOXICITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECRETION; T LYMPHOCYTE;

ALPHA-MACROGLOBULINS; ANTIVIRAL AGENTS; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GRANZYMES; HEME OXYGENASE-1; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; PEPTIDES; PHOSPHOPROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; VIRAL MATRIX PROTEINS;

EID: 80053898276     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-175     Document Type: Article

References (62)

1. Calderwood SK, Gong J, Theriault JR, Mambula SS, Gray PJ. Cell stress proteins: novel immunotherapeutics. Novartis Found Symp 2008, 291:115-131. discussion 131-140.
2. Beere HM. Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Invest 2005, 115:2633-2639. 10.1172/JCI26471, 1236700, 16200196.
3. Chen T, Guo J, Han C, Yang M, Cao X. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol 2009, 182:1449-1459.
4. Hoos A, Levey DL. Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Expert Rev Vaccines 2003, 2:369-379. 10.1586/14760584.2.3.369, 12903802.
5. Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, Parmiani G, Tosti G, Kirkwood JM, Hoos A, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 2008, 26:955-962. 10.1200/JCO.2007.11.9941, 18281670.
6. Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008, 372:145-154. 10.1016/S0140-6736(08)60697-2, 18602688.
7. Srivastava PK, Callahan MK, Mauri MM. Treating human cancers with heat shock protein-peptide complexes: the road ahead. Expert Opin Biol Ther 2009, 9:179-186. 10.1517/14712590802633918, 19236248.
8. Binder RJ, Srivastava PK. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol 2005, 6:593-599.
9. Flechtner JB, Cohane KP, Mehta S, Slusarewicz P, Leonard AK, Barber BH, Levey DL, Andjelic S. High-affinity interactions between peptides and heat shock protein 70 augment CD8+ T lymphocyte immune responses. J Immunol 2006, 177:1017-1027.
10. Valentinis B, Capobianco A, Esposito F, Bianchi A, Rovere-Querini P, Manfredi AA, Traversari C. Human recombinant heat shock protein 70 affects the maturation pathways of dendritic cells in vitro and has an in vivo adjuvant activity. J Leukoc Biol 2008, 84:199-206. 10.1189/jlb.0807548, 18456818.
11. Somersan S, Larsson M, Fonteneau JF, Basu S, Srivastava P, Bhardwaj N. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunol 2001, 167:4844-4852.
12. Bajor A, Tischer S, Figueiredo C, Wittmann M, Immenschuh S, Blasczyk R, Eiz-Vesper B. Modulatory role of calreticulin as chaperokine for dendritic cell-based immunotherapy. Clin Exp Immunol 165:220-234.
13. Binder RJ. Hsp receptors: the cases of identity and mistaken identity. Curr Opin Mol Ther 2009, 11:62-71.
14. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001, 14:303-313. 10.1016/S1074-7613(01)00111-X, 11290339.
15. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol 2000, 1:151-155. 10.1038/77835, 11248808.
16. Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, Stevenson MA, Calderwood SK. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002, 277:15028-15034. 10.1074/jbc.M200497200, 11836257.
17. Vabulas RM, Wagner H, Schild H. Heat shock proteins as ligands of toll-like receptors. Curr Top Microbiol Immunol 2002, 270:169-184. 10.1007/978-3-642-59430-4_11, 12467251.
18. Delneste Y, Magistrelli G, Gauchat J, Haeuw J, Aubry J, Nakamura K, Kawakami-Honda N, Goetsch L, Sawamura T, Bonnefoy J, Jeannin P. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 2002, 17:353-362. 10.1016/S1074-7613(02)00388-6, 12354387.
19. Becker T, Hartl FU, Wieland F. CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J Cell Biol 2002, 158:1277-1285. 10.1083/jcb.200208083, 2173242, 12356871.
20. SenGupta D, Norris PJ, Suscovich TJ, Hassan-Zahraee M, Moffett HF, Trocha A, Draenert R, Goulder PJ, Binder RJ, Levey DL, et al. Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II. J Immunol 2004, 173:1987-1993.
21. Einsele H, Kapp M, Grigoleit GU. CMV-specific T cell therapy. Blood Cells Mol Dis 2008, 40:71-75. 10.1016/j.bcmd.2007.07.002, 17851094.
22. Comoli P, Basso S, Labirio M, Baldanti F, Maccario R, Locatelli F. T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant. Blood Cells Mol Dis 2008, 40:68-70. 10.1016/j.bcmd.2007.06.020, 17904879.
23. Moosmann A, Bigalke I, Tischer J, Schirrmann L, Kasten J, Tippmer S, Leeping M, Prevalsek D, Jaeger G, Ledderose G, et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood
24. Feuchtinger T, Richard C, Joachim S, Scheible MH, Schumm M, Hamprecht K, Martin D, Jahn G, Handgretinger R, Lang P. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother 2008, 31:199-206. 10.1097/CJI.0b013e31815ef862, 18481389.
25. Brestrich G, Zwinger S, Roemhild A, Noutsias M, Rohde M, Keeren K, Sawitzki B, Volk HD, Reinke P, Hammer MH. Generation of HCMV-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy. J Immunother 2009, 32:932-940. 10.1097/CJI.0b013e3181b88fda, 19816188.
26. Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, Lin YF, Quiros-Tejeira RE, Reinke P, Schubert S, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006, 108:2942-2949. 10.1182/blood-2006-05-021782, 1895521, 16835376.
27. Hoffman JA. Adenovirus infections in solid organ transplant recipients. Curr Opin Organ Transplant 2009, 14:625-633. 10.1097/MOT.0b013e3283324e1b, 19741532.
28. Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, Kennedy-Nasser AA, Leung KS, Gee AP, Krance RA, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 2009, 114:4283-4292. 10.1182/blood-2009-07-232454, 2774556, 19700662.
29. Solache A, Morgan CL, Dodi AI, Morte C, Scott I, Baboonian C, Zal B, Goldman J, Grundy JE, Madrigal JA. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J Immunol 1999, 163:5512-5518.
30. Lilleri D, Fornara C, Chiesa A, Caldera D, Alessandrino EP, Gerna G. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 2008, 93:248-256. 10.3324/haematol.11912, 18245650.
31. Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 2003, 9:619-624. 10.1038/nm869, 12704385.
32. Paine A, Oelke M, Blasczyk R, Eiz-Vesper B. Expansion of human cytomegalovirus-specific T lymphocytes from unfractionated peripheral blood mononuclear cells with artificial antigen-presenting cells. Transfusion 2007, 47:2143-2152. 10.1111/j.1537-2995.2007.01439.x, 17958544.
33. Peggs KS, Verfuerth S, Pizzey A, Chow SL, Thomson K, Mackinnon S. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clin Infect Dis 2009, 49:1851-1860. 10.1086/648422, 19911966.
34. Rauser G, Einsele H, Sinzger C, Wernet D, Kuntz G, Assenmacher M, Campbell JD, Topp MS. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 2004, 103:3565-3572. 10.1182/blood-2003-09-3056, 14670917.
35. Figueiredo C, Wittmann M, Wang D, Dressel R, Seltsam A, Blasczyk R, Eiz-Vesper B. Heat shock protein 70 (HSP70) induces cytotoxicity of T-helper cells. Blood 2009, 113:3008-3016. 10.1182/blood-2008-06-162727, 19018093.
36. Blachere NE, Li Z, Chandawarkar RY, Suto R, Jaikaria NS, Basu S, Udono H, Srivastava PK. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 1997, 186:1315-1322. 10.1084/jem.186.8.1315, 2199095, 9334371.
37. Li Z. In vitro reconstitution of heat shock protein-peptide complexes for generating peptide-specific vaccines against cancers and infectious diseases. Methods 2004, 32:25-28. 10.1016/S1046-2023(03)00183-X, 14624873.
38. Paine A, Oelke M, Tischer S, Heuft HG, Blasczyk R, Eiz-Vesper B. Soluble recombinant CMVpp65 spanning multiple HLA alleles for reconstitution of antiviral CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation. J Immunother 33:60-72.
39. Watanabe K, Suzuki S, Kamei M, Toji S, Kawase T, Takahashi T, Kuzushima K, Akatsuka Y. CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy. Int J Hematol 2008, 88:311-320. 10.1007/s12185-008-0134-z, 18677654.
40. Vaz-Santiago J, Lule J, Rohrlich P, Jacquier C, Gibert N, Le Roy E, Betbeder D, Davignon JL, Davrinche C. Ex vivo stimulation and expansion of both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65. J Virol 2001, 75:7840-7847. 10.1128/JVI.75.17.7840-7847.2001, 115026, 11483727.
41. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996, 70:7569-7579. 190825, 8892876.
42. Zaia JA, Gallez-Hawkins G, Li X, Yao ZQ, Lomeli N, Molinder K, La Rosa C, Diamond DJ. Infrequent occurrence of natural mutations in the pp65(495-503) epitope sequence presented by the HLA A*0201 allele among human cytomegalovirus isolates. J Virol 2001, 75:2472-2474. 10.1128/JVI.75.5.2472-2474.2001, 114832, 11160752.
43. Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002, 20:4169-4180. 10.1200/JCO.2002.09.134, 12377960.
44. Castelli C, Ciupitu AM, Rini F, Rivoltini L, Mazzocchi A, Kiessling R, Parmiani G. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 2001, 61:222-227.
45. Rivoltini L, Castelli C, Carrabba M, Mazzaferro V, Pilla L, Huber V, Coppa J, Gallino G, Scheibenbogen C, Squarcina P, et al. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J Immunol 2003, 171:3467-3474.
46. Castellino F, Boucher PE, Eichelberg K, Mayhew M, Rothman JE, Houghton AN, Germain RN. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med 2000, 191:1957-1964. 2213527, 10839810.
47. Noessner E, Gastpar R, Milani V, Brandl A, Hutzler PJ, Kuppner MC, Roos M, Kremmer E, Asea A, Calderwood SK, Issels RD. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol 2002, 169:5424-5432.
48. Binder RJ, Srivastava PK. Essential role of CD91 in re-presentation of gp96-chaperoned peptides. Proc Natl Acad Sci USA 2004, 101:6128-6133. 10.1073/pnas.0308180101, 395934, 15073331.
49. Matsutake T, Sawamura T, Srivastava PK. High efficiency CD91- and LOX-1-mediated re-presentation of gp96-chaperoned peptides by MHC II molecules. Cancer Immun 10:7.
50. Kern F, Bunde T, Faulhaber N, Kiecker F, Khatamzas E, Rudawski IM, Pruss A, Gratama JW, Volkmer-Engert R, Ewert R, et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis 2002, 185:1709-1716. 10.1086/340637, 12085315.
51. Bao L, Dunham K, Stamer M, Mulieri KM, Lucas KG. Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:1156-1162. 10.1016/j.bbmt.2008.07.014, 2605082, 18804046.
52. Lacey SF, Villacres MC, La Rosa C, Wang Z, Longmate J, Martinez J, Brewer JC, Mekhoubad S, Maas R, Leedom JM, et al. Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol 2003, 64:440-452. 10.1016/S0198-8859(03)00028-4, 12651070.
53. Navaratnam M, Deshpande MS, Hariharan MJ, Zatechka DS, Srikumaran S. Heat shock protein-peptide complexes elicit cytotoxic T-lymphocyte and antibody responses specific for bovine herpesvirus 1. Vaccine 2001, 19:1425-1434. 10.1016/S0264-410X(00)00381-9, 11163665.
54. Han Y, Guo Q, Zhang M, Chen Z, Cao X. CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol 2009, 182:111-120.
55. Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, Greenberg PD. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007, 110:201-210. 10.1182/blood-2006-11-056168, 1896114, 17371945.
56. Clerget M, Polla BS. Erythrophagocytosis induces heat shock protein synthesis by human monocytes-macrophages. Proc Natl Acad Sci USA 1990, 87:1081-1085. 10.1073/pnas.87.3.1081, 53414, 2153967.
57. Tacchini L, Schiaffonati L, Pappalardo C, Gatti S, Bernelli-Zazzera A. Expression of HSP 70, immediate-early response and heme oxygenase genes in ischemic-reperfused rat liver. Lab Invest 1993, 68:465-471.
58. Biburger M, Theiner G, Schadle M, Schuler G, Tiegs G. Pivotal Advance: Heme oxygenase 1 expression by human CD4+ T cells is not sufficient for their development of immunoregulatory capacity. J Leukoc Biol 87:193-202.
59. Andersen MH, Sorensen RB, Brimnes MK, Svane IM, Becker JC, thor Straten P. Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J Clin Invest 2009, 119:2245-2256. 10.1172/JCI38739, 2719937, 19662679.
60. Maeda H, Sahara H, Mori Y, Torigo T, Kamiguchi K, Tamura Y, Tamura Y, Hirata K, Sato N. Biological heterogeneity of the peptide-binding motif of the 70-kDa heat shock protein by surface plasmon resonance analysis. J Biol Chem 2007, 282:26956-26962. 10.1074/jbc.M703436200, 17626008.
61. York IA, Goldberg AL, Mo XY, Rock KL. Proteolysis and class I major histocompatibility complex antigen presentation. Immunol Rev 1999, 172:49-66. 10.1111/j.1600-065X.1999.tb01355.x, 10631936.
62. Lund BT, Chakryan Y, Ashikian N, Mnatsakanyan L, Bevan CJ, Aguilera R, Gallaher T, Jakowec MW. Association of MBP peptides with Hsp70 in normal appearing human white matter. J Neurol Sci 2006, 249:122-134. 10.1016/j.jns.2006.05.066, 16842822.